94 related articles for article (PubMed ID: 30768824)
1. Body mass index and insulin use as identifiers of high-cost patients with type 2 diabetes: A retrospective analysis of electronic health records linked to insurance claims data.
Johnston SS; Ammann EM; Kashyap SR; Stokes A; Hsiao CC; Daskiran M; Scamuffa R
Diabetes Obes Metab; 2019 Jun; 21(6):1419-1428. PubMed ID: 30768824
[TBL] [Abstract][Full Text] [Related]
2. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes.
Paul SK; Shaw JE; Montvida O; Klein K
Diabetes Obes Metab; 2016 Dec; 18(12):1244-1252. PubMed ID: 27502528
[TBL] [Abstract][Full Text] [Related]
3. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I
Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951
[TBL] [Abstract][Full Text] [Related]
4. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
[TBL] [Abstract][Full Text] [Related]
5. Real-world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: A German claims data analysis.
Gabler M; Picker N; Geier S; Foersch J; Aberle J; Martin S; Riedl M; Wilke T
Diabetes Res Clin Pract; 2021 Apr; 174():108734. PubMed ID: 33737213
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
Dalal MR; Kazemi M; Ye F; Xie L
Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
[TBL] [Abstract][Full Text] [Related]
7. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
Kong AM; Farahbakhshian S; Pendergraft T; Brouillette MA; Mukherjee B; Smith DM; Sheehan JJ
Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.
Chitnis AS; Ganz ML; Benjamin N; Langer J; Hammer M
Adv Ther; 2014 Sep; 31(9):986-99. PubMed ID: 25245811
[TBL] [Abstract][Full Text] [Related]
9. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.
Yu AP; Wu EQ; Birnbaum HG; Emani S; Fay M; Pohl G; Wintle M; Yang E; Oglesby A
Curr Med Res Opin; 2007 Sep; 23(9):2157-69. PubMed ID: 17669232
[TBL] [Abstract][Full Text] [Related]
10. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
Pagidipati NJ; Zheng Y; Green JB; McGuire DK; Mentz RJ; Shah S; Aschner P; Delibasi T; Rodbard HW; Westerhout CM; Holman RR; Peterson ED;
Am Heart J; 2020 Jan; 219():47-57. PubMed ID: 31707324
[TBL] [Abstract][Full Text] [Related]
11. The effects of patient out-of-pocket costs for insulin on medication adherence and health care utilization in patients with commercial insurance; 2007-2018.
McAdam-Marx C; Ruiz-Negron N; Sullivan JM; Tucker JM
J Manag Care Spec Pharm; 2022 May; 28(5):494-506. PubMed ID: 35392659
[No Abstract] [Full Text] [Related]
12. The Economic Burden of Obesity by Glycemic Stage in the United States.
Li Q; Blume SW; Huang JC; Hammer M; Graf TR
Pharmacoeconomics; 2015 Jul; 33(7):735-48. PubMed ID: 25564434
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of the clinical benefits of bariatric surgery in diabetes patients with BMI ≥35 kg/m².
Klein S; Ghosh A; Cremieux PY; Eapen S; McGavock TJ
Obesity (Silver Spring); 2011 Mar; 19(3):581-7. PubMed ID: 20829800
[TBL] [Abstract][Full Text] [Related]
14. Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America.
Elgart JF; Prestes M; Gonzalez L; Rucci E; Gagliardino JJ;
PLoS One; 2017; 12(12):e0189755. PubMed ID: 29261739
[TBL] [Abstract][Full Text] [Related]
15. Variation in the risk of progression between glycemic stages across different levels of body mass index: evidence from a United States electronic health records system.
Blume SW; Li Q; Huang JC; Hammer M; Graf TR
Curr Med Res Opin; 2015 Jan; 31(1):115-24. PubMed ID: 25266974
[TBL] [Abstract][Full Text] [Related]
16. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
Misurski D; Lage MJ; Fabunmi R; Boye KS
Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
[TBL] [Abstract][Full Text] [Related]
17. The clinical and economic impact of the use of diabetes-specific enteral formula on ICU patients with type 2 diabetes.
Han YY; Lai SR; Partridge JS; Wang MY; Sulo S; Tsao FW; Hegazi RA
Clin Nutr; 2017 Dec; 36(6):1567-1572. PubMed ID: 27765525
[TBL] [Abstract][Full Text] [Related]
18. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
19. Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity.
Boye KS; Lage MJ; Terrell K
J Diabetes Complications; 2020 Dec; 34(12):107730. PubMed ID: 32943301
[TBL] [Abstract][Full Text] [Related]
20. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
